Atezolizumab plus cabozantinib for teen osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are at least 12 years old when you sign consent
- Your osteosarcoma diagnosis has been confirmed by pathology (biopsy/tissue test)
- Your cancer is recurrent, relapsed, or cannot be fully removed, and has measurable tumors
- You have already tried standard chemotherapy (including some of cisplatin, doxorubicin, methotrexate, and/or ifosfamide) and it didn’t work well
- You can provide tumor tissue for testing (archived sample within 6 months, or a new biopsy at screening if needed)
- Your blood counts, liver/kidney tests, and overall health are strong enough to safely start study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This research study follows young people newly diagnosed with osteosarcoma (a type of bone cancer) who are receiving standard chemotherapy. Researchers will collect information about how the cancer responds to treatment and study biological samples to better understand the disease.
Hear when a new Metastatic Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.